The United Kingdom and the United States have forged a important bilateral deal that will keep zero levies on British pharmaceutical exports going into the US market.
The Terms of the Deal
As part of the deal, the UK has committed to increase expenditure on medicines through the NHS. This pledge ensures that duties on these key goods will be held at zero for a timeframe of 36 months.
This agreement is in response to previous warnings to significantly raise tariffs on patented pharmaceutical imports, with increases floated as high as double the cost.
"This arrangement between the UK strengthens the global environment for cutting-edge drugs and brings long-overdue equity to U.S.–U.K. pharmaceutical trade," an announcement declared.
Trade Importance
Medicines constitute one of the Britain's largest goods shipped to the America, which is easily the biggest destination for large companies like GSK and AstraZeneca.
Statistics show that in the one-year period leading up to last September, the UK exported pharmaceutical products totaling billions to the US. This amount accounted for a significant portion of total UK exports in that period.
"This agreement safeguards work, stimulates capital expenditure and facilitates the UK to become a global hub for biotech and pharma," the Business and Trade Secretary stated.
Specific British Pledges
The deal includes several key pledges from the UK:
- Revised Affordability Limit: The UK will lift the cost ceiling at which it deems new medicines to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a target to raise overall NHS spending on medicines from 0.3% of the national economy to 0.6 percent over the coming ten years.
- Refund Ceiling: The sum drug companies must return to the NHS to stay within budget will be limited at fifteen percent. In the past, repayments exceeded 20%.
Industry Background
This agreement comes amid a ongoing row between the pharmaceutical industry and the ministers over drug pricing and regulatory access.
The disagreement were intensified by assertions that American customers were paying a premium for the identical medicines than patients in the UK and Europe.
Recently, several major drug company projects in the UK have been halted or cancelled, while major funding commitments have been announced toward American operations.
A senior figure acknowledged that the NHS must invest a greater share on medicines, noting that its spending on drugs had shrunk as a share of its resources over the previous ten-year period.
